Gemtuzumab ozogamicin

From Wikipedia, the free encyclopedia

You have new messages (last change).
Image:Gemtuzumab ozogamicin.png
Gemtuzumab ozogamicin
Systematic (IUPAC) name
Humanized chimeric anti-CD33 antibody
Identifiers
CAS number 220578-59-6
ATC code L01XC05
PubChem  ?
DrugBank BTD00077
Chemical data
Formula  ?
Mol. weight  ?
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes  ?

Gemtuzumab ozogamicin (marketed as Mylotarg) is a monoclonal antibody used to treat acute myelogenous leukemia.

It is a monoclonal antibody to CD33 linked to a cytotoxic agent, calicheamicin. CD33 is expressed in most leukemic blast cells but is not found on normal hematopoietic stem cells. When given to patients in first relapse, 15% of patients achieve a complete remission. In the United States, it was approved by the FDA for use in patients over the age of 60 with relapsed AML who are not considered candidates for standard chemotherapy.[1]

A notable complication of therapy with gemtuzumab is the increased risk of veno-occlusive disease in the absence of bone marrow transplantation.[2] The onset of VOD can also be delayed and can occur at increased frequency following bone marrow transplantation.[3]

[edit] References

  1. ^ Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R (2001). "Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.". Clin Cancer Res 7 (6): 1490-6. PMID 11410481.
  2. ^ Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH (2001). "Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.". Cancer 92 (2): 406-13. PMID 11466696.
  3. ^ Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ (2003). "Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.". Blood 102 (5): 1578-82. PMID 12738663.


Chemotherapeutic agents/Antineoplastic agents (L01) edit - Chemotherapy regimens
Alkylating agents:

Nitrogen mustards: ( Chlorambucil, Chlormethine, Cyclophosphamide, Ifosfamide, Melphalan). Nitrosoureas: ( Carmustine, Fotemustine, Lomustine, Streptozocin). Platinum: ( Carboplatin, Cisplatin, Oxaliplatin, BBR3464). Busulfan, Dacarbazine, Mechlorethamine, Procarbazine, Temozolomide, ThioTEPA, Uramustine
Antimetabolites:

Folic acid: ( Methotrexate, Pemetrexed, Raltitrexed). Purine: ( Cladribine, Clofarabine, Fludarabine, Mercaptopurine, Tioguanine). Pyrimidine: ( Capecitabine). Cytarabine, Fluorouracil, Gemcitabine
Plant alkaloids:

Taxane: ( Docetaxel, Paclitaxel). Vinca: ( Vinblastine, Vincristine, Vindesine, Vinorelbine).
Cytotoxic/antitumor antibiotics:

Anthracycline family: (Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, Valrubicin). Bleomycin, Hydroxyurea, Mitomycin
Topoisomerase inhibitors:

Topotecan, Irinotecan, Podophyllum: ( Etoposide, Teniposide).
Monoclonal antibodies:

Alemtuzumab, Bevacizumab, Cetuximab, Gemtuzumab, Panitumumab, Rituximab, Trastuzumab
Photosensitizers:

Aminolevulinic acid, Methyl aminolevulinate, Porfimer sodium, Verteporfin
Kinase inhibitors:

Dasatinib, Erlotinib, Gefitinib, Imatinib, Lapatinib, Nilotinib, Sorafenib, Sunitinib, Vandetanib (ZD6474)
Other:

Alitretinoin, Altretamine, Amsacrine, Anagrelide, Arsenic trioxide, Asparaginase, Bexarotene, Bortezomib, Denileukin diftitox, Estramustine, Hydroxycarbamide, Pentostatin, Masoprocol, Mitotane, Pegaspargase, Tretinoin
Pills  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
Retrieved from "http://en.wikipedia.org../../../g/e/m/Gemtuzumab_ozogamicin.html"